Abstracts tagged "Scleroderma, Systemic"

Abstract Number: 0392 • ACR Convergence 2020
Prevalence and Survival of Systemic Sclerosis (SSc) and Associated Interstitial Lung Disease (ILD) in Ontario, Canada over 10 Years
Janet Pope¹, Kobina Quansah², Martin Kolb³, Jason Flavin⁴, Hassan Shazia⁵ and Soo Jin Seung⁵, ¹Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ²Boehringer Ingelheim (Canada) Limited, Burlington, ON, Canada, ³McMaster University and Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamliton, ON, Canada, ⁴Boehringer Ingelheim, Corporate Headquarters, Burlington, ON, Canada, ⁵HOPE Research Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by skin thickening, vascular lesions and fibrotic changes in various organs, mainly the lungs, heart, intestinal…
Abstract Number: 1384 • ACR Convergence 2020
Usage, Needs and Preferences Regarding Physical Therapy in Patients with Systemic Sclerosis
Sophie Liem¹, Nina van Leeuwen², Thea Vliet Vlieland³, Lian de Pundert⁴, Rita Schriemer⁵, Julia Spierings⁶, Madelon Vonk⁷ and Jeska de Vries-Bouwstra¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²LUMC, Leiden, Netherlands, ³Leiden University Medical Center, 2300 RC Leiden, Netherlands, ⁴HAGA Hospital, The Hague, Netherlands, ⁵NVLE, Utrecht, ⁶University Medical Center Utrecht, Maastricht, Netherlands, ⁷Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Netherlands
Background/Purpose: The importance of non-pharmacologic interventions in systemic sclerosis (SSc) is increasingly recognized. Physical therapy is among the most frequently used interventions, but knowledge on…
Abstract Number: 0394 • ACR Convergence 2020
Prevalence of a Diagnosis of Osteopenia/Osteoporosis Amongst Patients with Systemic Sclerosis and Identification of Associated Clinical Factors
Guanying Wang¹, Diane Mar², Joy Wu³, Julia Simard⁴, Rita Popat¹ and Lorinda Chung⁵, ¹Department of Epidemiology & Population Health, Stanford University School of Medicine, Palo Alto, CA, ²Stanford Department of Immunology/Rheumatology, Palo Alto, CA, ³Department of Medicine, Division of Endocrinology, Stanford University School of Medicine, Palo Alto, CA, ⁴Stanford Medicine, Stanford, CA, ⁵Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA
Background/Purpose: This study aims to determine the prevalence of a diagnosis of osteopenia/osteoporosis (OP) in systemic sclerosis (SSc) patients and to identify the clinical and…
Abstract Number: 1385 • ACR Convergence 2020
Physical Therapy in Patients with Systemic Sclerosis: The Perspective of Physical Therapists on Current Delivery and Educational Needs
Sophie Liem¹, Nina van Leeuwen², Thea Vliet Vlieland³, Lian de Pundert⁴, Rita Schriemer⁵, Julia Spierings⁶, Madelon Vonk⁷ and Jeska de Vries-Bouwstra¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²LUMC, Leiden, Netherlands, ³Leiden University Medical Center, 2300 RC Leiden, Netherlands, ⁴HAGA Hospital, The Hague, Netherlands, ⁵NVLE, Utrecht, ⁶University Medical Center Utrecht, Maastricht, Netherlands, ⁷Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Netherlands
Background/Purpose: As there is currently no cure available for systemic sclerosis (SSc), nonpharmacologic care is an essential element in the management of the disease. Physical…
Abstract Number: 0402 • ACR Convergence 2020
Optical Coherence Tomography of the Skin Detects Scleroderma Changes in Clinically Unaffected Skin: An Opportunity for Early Detection of Systemic Sclerosis
Giuseppina Abignano¹, Duygu Temiz Karadag², Ozcan Gundogdu³, Giovanni Lettieri⁴, Maria Carmela Padula⁵, Angela A Padula⁵, Paul Emery⁶, Salvatore D'Angelo⁵ and Francesco Del Galdo⁶, ¹Rheumatology Institute of Lucania (IReL), Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Potenza, Italy, ²Rheumatology Institute of Lucania (IReL), Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy and Department of Rheumatology, Kocaeli University, Kocaeli, Turkey, Kocaeli, Turkey, ³Department of Biomedical Engineering, Kocaeli University, Kocaeli,Turkey, Kocaeli, Turkey, ⁴Radiology Department, San Carlo Hospital, Potenza, Italy, Potenza, Italy, ⁵Rheumatology Institute of Lucania (IReL), Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy, Potenza, Italy, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom
Background/Purpose: The Very Early Diagnosis Of Systemic Sclerosis (VEDOSS) study has shown that more than 80% of patients with Raynaud’s Phenomenon, specific ANA positivity and…
Abstract Number: 1389 • ACR Convergence 2020
Clinical Characteristics and Treatment Outcome of a Cohort of Patients with Joint and Fascial Involvement in the Context of Chronic Graft versus Host Disease
Cristina Hidalgo Calleja¹, Concepción Román Curto², Luis Gómez-Lechón³, Maria Elisa Acosta², Olga Compán⁴, Sonia Pastor², Carlos Montilla Morales², Lucía Pantoja Zarza⁵, María Dolores Sánchez González⁶ and Lucía López Corral², ¹Hospital Universitario Salamanca, Salamanca, Spain, ²Hospital Universitario de Salamanca, Salamanca, Spain, ³Hospital Francesc de Borga de Gandía, Valencia, Spain, ⁴Hospital Universitario de Salamanca, ´Salamanca, Spain, ⁵Complejo Asistencial Hospital General de Segovia, Segovia, Spain, ⁶Hospital Clínico Universitario de Valladolid, Valladolid, Spain
Background/Purpose: Chronic graft-vs-host disease (cGVHD) is a major late complication of allogeneic hematopoietic stem cell transplantation (alloHSCT), typically occurring within three years post-transplant and affecting…
Abstract Number: 0916 • ACR Convergence 2020
Validating Autoantibody Associations and Clinical Impact of Severe Gastrointestinal Involvement in Systemic Sclerosis
Fiza Ahmed¹, Svetlana Nihtyanova¹, Stamatia Chatzinikolaou², Voon Ong¹, Charles Murray² and Christopher Denton³, ¹Centre for Rheumatology, Royal Free Campus, UCL Division of Medicine, UK, London, United Kingdom, ²Department of Gastroenterology, Royal Free London Foundation Trust, UK, London, United Kingdom, ³University College London, London, United Kingdom
Background/Purpose: Patients with systemic sclerosis (SSc) frequently experience gastrointestinal (GI) symptoms, ranging from mild to debilitating in severity. Better prediction of those most at risk…
Abstract Number: 1390 • ACR Convergence 2020
Outcomes of Systemic Sclerosis Patients Who Were Primarily Admitted for Acute Myocardial Infarction from 2016 to 2017: Insights from the National Inpatient Sample
Atefeh Vafa¹, Omid Behnamfar² and Yih Chang Lin³, ¹University of South Florida, Tampa, FL, ²University of California San Diego, La Jolla, CA, ³University of South Florida, Morsani College of Medicine, Tampa, FL
Background/Purpose: Several systemic autoimmune rheumatic diseases have been shown to increase coronary artery disease (CAD) risk, notable rheumatoid arthritis and systemic lupus erythematosus. However, data…
Abstract Number: 0919 • ACR Convergence 2020
Determinants of Health-related Quality of Life in Systemic Sclerosis
Nina van Leeuwen¹, Jacopo Ciaffi², Sophie Liem², Thomas Huizinga² and Jeska de Vries-Bouwstra², ¹LUMC, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Systemic Sclerosis (SSc) is a heterogeneous disease, in which multiple manifestations are associated with considerable morbidity and mortality. Cross sectional studies have shown that…
Abstract Number: 1391 • ACR Convergence 2020
Associations Between Autoantibodies in Systemic Sclerosis and Cancer in a National Registry
Selma Lazizi¹, Marie Hudson², Murray Baron³, Marvin Fritzler⁴ and Sabrina Hoa⁵, ¹Université de Montréal, Montreal, QC, Canada, ²Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, ³Jewish General Hospital, Montreal, QC, Canada, ⁴Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada
Background/Purpose: Autoantibodies are useful in systemic sclerosis (SSc) for predicting disease course. Some autoantibodies have been associated with a close temporal relationship with cancer. We…
Abstract Number: 0920 • ACR Convergence 2020
Machine Learning Assisted Prediction of Progression in Systemic Sclerosis Patients: An Approach to Concise, Tailored Model Construction Using Outpatient Clinical Data
Nina van Leeuwen¹, Marc Maurits², Sophie Liem², Jacopo Ciaffi², Nina Ajmone Marsan², Maarten Ninaber², Thomas Huizinga² and Jeska de Vries-Bouwstra², ¹LUMC, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Systemic Sclerosis (SSc) disease course can range from mild, to very severe with progressive organ involvement within months. Guidelines for follow-up are mainly based…
Abstract Number: 1396 • ACR Convergence 2020
Digital Artery Volume Index (Davix©) Predicts Onset of Future Digital Ulcers in Patients with Systemic Sclerosis
Klodian Gjeloshi¹, Giovanni Lettieri², Fiammetta Danzo¹, Giuseppina Abignano³, Mark Hinton⁴, Anne-Maree Dean⁵, Giovanna Cuomo⁶, Olga Kubassova⁷ and Francesco Del Galdo⁵, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK and Internal Medicine Department, University of Campania Luigi Vanvitelli, Naples, Italy, Leeds, United Kingdom, ²Radiology Department, San Carlo Hospital, Potenza, Italy, Potenza, Italy, ³Rheumatology Institute of Lucania (IReL), Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, England, United Kingdom, ⁴IAG CEO, London, United Kingdom, London, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom, ⁶Internal Medicine Department, University of Campania Luigi Vanvitelli, Naples, Italy, Naples, Italy, ⁷Image Analysis Group, London, United Kingdom
Background/Purpose: Neointima proliferation is a key pathologic feature of Systemic Sclerosis (SSc), causing arterial vessel narrowing. It is a recognised culprit pathological lesion in Digital…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].